SGYP Share Price

Open 5.45 Change Price %
High 5.53 1 Day 0.01 0.18
Low 5.34 1 Week -0.58 -9.56
Close 5.49 1 Month -0.07 -1.26
Volume 5190094 1 Year 1.79 48.38
52 Week High 7.15
52 Week Low 2.50
SGYP Important Levels
Resistance 2 5.67
Resistance 1 5.59
Pivot 5.45
Support 1 5.39
Support 2 5.31
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP)

SGYP Technical Analysis 1.5
As on 24th Feb 2017 SGYP Share Price closed @ 5.49 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4.67 & Sell for SHORT-TERM with Stoploss of 5.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGYP Target for February
1st Target up-side 8.05
2nd Target up-side 8.74
3rd Target up-side 9.43
1st Target down-side 6.09
2nd Target down-side 5.4
3rd Target down-side 4.71
SGYP Other Details
Segment EQ
Market Capital 240850608.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.synergypharma.com
SGYP Address
SGYP
420 Lexington Avenue
Suite 2012
New York, NY 10170
United States
Phone: 212-297-0020
Fax: 212-297-0019
SGYP Latest News
Interactive Technical Analysis Chart Synergy Pharmaceuticals, Inc. ( SGYP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Synergy Pharmaceuticals, Inc.
SGYP Business Profile
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.